NEWS
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11,
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company developing cell
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company developing cell
Immix Biopharma Announces Other Serious Diseases Strategy
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – –
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication